With new drugs for brain cancer and breast cancer treatment nearing the end of clinical trials, Celldex Therapeutics Inc. (CLDX, Financial) is up 223% over the last 12 months.
After increasing his Celldex Therapeutics (CLDX) position on April 1, 2013, by 45.61%, Guru Steven Cohen has added again, this time 9.88%, as of April 12, 2013, trading at a price range of $11.94. After the trade Cohen owns 4,319,837 shares of the biopharmaceutical company or 5.36% of shares outstanding.
Cohen’s holding history shows an average cost per share for 2.7 million shares is $5, with a 160% gain since he first bought in first quarter of 2012:
Celldex Therapeutics Inc. is a biopharmaceutical company focused on immunotherapy technologies and drugs for difficult-to-treat diseases. As the “first antibody-based combination immunotherapy company,” Celldex has a full product pipeline of eight cancer-fighting drugs in development, using technology that can target disease at a molecular scale. For example, the company’s lead brain cancer drug candidate, known as CDX-110, targets the tumor-specific molecule, and is entering a Phase 3 clinical trial for an aggressive brain cancer. Breast cancer drug candidate, known as CDX-011, is currently undergoing evaluation in a Phase 2b clinical trial.
The current CLDX share price is $13.01, with a change from average up 9%.
The company has a market cap of $1.01 billion. The P/B ratio is 10.9, and the P/S ratio is 67.1. Here’s a detailed analysis of Celldex Therapeutics Inc.
Celldex Therapeutics Inc. reported a net loss of $16.8 million for the fourth quarter of 2012 compared to a net loss of $12.7 million for the fourth quarter of 2011. For the 12 months ended Dec. 31, 2012, Celldex reported a net loss of $59.1 million compared to a net loss of $44.8 million for the 12 months ended Dec. 31, 2011. Celldex Therapeutics also reported cash, cash equivalents and marketable securities of $84 million. As of Feb. 28, 2013, Celldex had cash, cash equivalents and marketable securities of approximately $189 million.
Guru Cohen is poised to profit on Celldex product releases when three clinical studies are completed by the end of 2013 and potentially, the company’s new drugs can go to a ready market.
Steven A. Cohen is a billionaire hedge fund investor and the founder and manager of SAC Capital Advisors. As of April 8, 2013, SAC Capital’s portfolio shows 1,585 stocks at a total value of $20.3 billion, and a quarter-over-quarter turnover of 42%. In that update, the SAC Capital Advisors portfolio lists 429 new stocks.
Steven Cohen’s top buys, sells and holdings:
After increasing his Celldex Therapeutics (CLDX) position on April 1, 2013, by 45.61%, Guru Steven Cohen has added again, this time 9.88%, as of April 12, 2013, trading at a price range of $11.94. After the trade Cohen owns 4,319,837 shares of the biopharmaceutical company or 5.36% of shares outstanding.
Cohen’s holding history shows an average cost per share for 2.7 million shares is $5, with a 160% gain since he first bought in first quarter of 2012:
Celldex Therapeutics Inc. is a biopharmaceutical company focused on immunotherapy technologies and drugs for difficult-to-treat diseases. As the “first antibody-based combination immunotherapy company,” Celldex has a full product pipeline of eight cancer-fighting drugs in development, using technology that can target disease at a molecular scale. For example, the company’s lead brain cancer drug candidate, known as CDX-110, targets the tumor-specific molecule, and is entering a Phase 3 clinical trial for an aggressive brain cancer. Breast cancer drug candidate, known as CDX-011, is currently undergoing evaluation in a Phase 2b clinical trial.
The current CLDX share price is $13.01, with a change from average up 9%.
The company has a market cap of $1.01 billion. The P/B ratio is 10.9, and the P/S ratio is 67.1. Here’s a detailed analysis of Celldex Therapeutics Inc.
Celldex Therapeutics Inc. reported a net loss of $16.8 million for the fourth quarter of 2012 compared to a net loss of $12.7 million for the fourth quarter of 2011. For the 12 months ended Dec. 31, 2012, Celldex reported a net loss of $59.1 million compared to a net loss of $44.8 million for the 12 months ended Dec. 31, 2011. Celldex Therapeutics also reported cash, cash equivalents and marketable securities of $84 million. As of Feb. 28, 2013, Celldex had cash, cash equivalents and marketable securities of approximately $189 million.
Guru Cohen is poised to profit on Celldex product releases when three clinical studies are completed by the end of 2013 and potentially, the company’s new drugs can go to a ready market.
Steven A. Cohen is a billionaire hedge fund investor and the founder and manager of SAC Capital Advisors. As of April 8, 2013, SAC Capital’s portfolio shows 1,585 stocks at a total value of $20.3 billion, and a quarter-over-quarter turnover of 42%. In that update, the SAC Capital Advisors portfolio lists 429 new stocks.
Steven Cohen’s top buys, sells and holdings:
